UroGen Highlights Publication Of Phase 3 ENVISION Study Data In Journal of Urology Showing Patients Receiving UGN-102 Had A 79.6% Complete Response Rate At Three Months
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma announced the publication of Phase 3 ENVISION study data in the Journal of Urology, showing that patients receiving UGN-102 had a 79.6% complete response rate at three months.
October 28, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UroGen Pharma's Phase 3 ENVISION study data published in the Journal of Urology shows a 79.6% complete response rate for UGN-102 at three months, indicating strong efficacy.
The publication of positive Phase 3 study results for UGN-102 in a reputable journal is likely to boost investor confidence and positively impact UroGen Pharma's stock price. The high complete response rate suggests strong efficacy, which is critical for the product's success and market potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100